CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 3,687 enrolled
Drug / intervention
XIENCE V® Everolimus Eluting Coronary Stent +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00307047
NCT00307047Phase 3Completed
CompareCT.gov

SPIRIT IV Clinical Trial: Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in the Treatment of Subjects With de Novo Native Coronary Artery Lesions

Abbott Medical Devices·interventional·Posted Mar 27, 2006·Updated Nov 7, 2012

In Brief

A Phase 3 clinical trial evaluating XIENCE V® Everolimus Eluting Coronary Stent and TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent for Coronary Artery Disease. Completed, enrolled 3,687 participants across 65 sites.

Detailed Summary

The purpose of the SPIRIT IV Clinical Trial is to continue to evaluate the safety and efficacy of the XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V®). The XIENCE V® arm will be compared to an active control, represented by the FDA-approved TAXUS® EXPRESS2™ Paclitaxel-Eluting Coronary Stent System (TAXUS®), commercially available from Boston Scientific. TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent System is manufactured by Boston Scientific.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Artery Disease
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 27, 2006
Enrollment StartAug 1, 2006
Primary CompletionAug 1, 2009
Study CompletionMay 1, 2012
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 20.3 years ago

Interventions

XIENCE V® Everolimus Eluting Coronary Stentdevice

Drug eluting stent implantation stent in the treatment of coronary artery disease.

TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stentdevice

Drug eluting stent implantation stent in the treatment of coronary artery disease.